

# CONTENTS

|  |     |
|--|-----|
| INTRODUCTION .....   | 1   |
| AIM OF THE WORK .....  | 3   |
| REVIEW OF LITERATURE.....                                      |     |
| * Spontaneous bacterial peritonitis.....                       |     |
| -Definition .....  | 4   |
| -Epidemiology.....   | 4   |
| -Risk factors .....  | 5   |
| -Variants of SBP.....  | 6   |
| -Causes.....   | 10  |
| -Pathogenesis .....  | 11  |
| -Clinical presentation .....                                   | 15  |
| -Differential diagnosis.....                                   | 16  |
| -Diagnosis.....  | 16  |
| -Treatment.....  | 28  |
| -Prophylaxis.....  | 35  |
| -Complications.....  | 40  |
| -Prognosis.....  | 43  |
| * Lactoferrin .....  |     |
| -Definition.....   | 44  |
| -Structure and properties.....                                 | 45  |
| -Source of lactoferrin.....                                    | 47  |
| -Regulation of synthesis.....                                  | 49  |
| -Lactoferrin receptors.....                                    | 49  |
| -Lactoferrin metabolism.....                                   | 50  |
| -Biological functions of lactoferrin.....                      | 50  |
| * Lactoferrin and iron metabolism .....                        | 50  |
| * Antimicrobial functions .....                                | 52  |
| * Lactoferrin and tumour growth .....                          | 56  |
| * Lactoferrin and cell proliferation and differentiation ..... | 57  |
| * Lactoferrin and bone .....                                   | 57  |
| * Enzymatic activity of ribonuclease .....                     | 58  |
| -Role of Lactoferrin in inflammatory diarrhea .....            | 58  |
| - Role of Lactoferrin in SBP .....                             | 60  |
| PATIENTS AND METHODS .....                                     | 61  |
| RESULTS.....   | 70  |
| DISCUSSION.....  | 90  |
| SUMMARY.....   | 97  |
| CONCLUSION.....  | 100 |
| RECOMMENDATIONS.....   | 101 |
| REFERENCES.....  | 102 |
| ARABIC SUMMARY.....  | 1-2 |

## LIST OF TABLES

| Table | Title   | Page |
|-------|---|------|
| I     | Sensitivity and specificity of ascitic PMN count in SBP.  | 20   |
| 1     | An overview on the relevant history and clinical data of the studied cases.                     | 70   |
| 2     | Clinical examination of all studied cases.  | 71   |
| 3     | Classification of the studied cases according to modified Child's Pugh Classification.          | 72   |
| 4     | Classification of the studied cases according to ascitic fluid PMN count.                       | 73   |
| 5     | General features of SBP and non SBP groups.   | 74   |
| 6     | Clinical presentation of studied groups.  | 75   |
| 7     | Clinical examination of studied groups.   | 77   |
| 8     | Laboratory investigations of studied groups.  | 78   |
| 9     | Abdominal ultrasonographic findings among studied cases.  | 79   |
| 10    | Child's Pugh classification of both groups.   | 81   |
| 11    | Ascitic fluid physical examination among studied cases.   | 82   |
| 12    | Ascitic fluid characters of both groups (cell count and chemical analysis).                     | 83   |
| 13    | Ascitic fluid characters of both groups (cell count in comparison between AFLAC and Multistix). | 84   |
| 14    | Impact of treatment on ascitic fluid chemical composition among the SBP group.                  | 85   |
| 15    | Impact of treatment on the results of multistixs among the SBP group.                           | 86   |
| 16    | Cut off value, sensitivity, specificity and accuracy of AFLAC to diagnose SBP.                  | 88   |
| 17    | Sensitivity, specificity and accuracy of Multistixs for diagnosis of SBP.                       | 89   |

## LIST OF FIGURES

| <b>Fig.</b> | <b>Title</b>  | <b>Page</b> |
|-------------|---|-------------|
| <b>1</b>    | studied patients according to gender  | <b>70</b>   |
| <b>2</b>    | Blood pressure in studied patients  | <b>72</b>   |
| <b>3</b>    | Classification of the studied cases according to Modified Child's Pugh Classification | <b>72</b>   |
| <b>4</b>    | Classification of the studied cases according to ascitic fluid PMN count              | <b>73</b>   |
| <b>5</b>    | Age of studied groups   | <b>74</b>   |
| <b>6</b>    | studied groups according to gender  | <b>75</b>   |
| <b>7</b>    | Clinical presentation of studied groups   | <b>76</b>   |
| <b>8</b>    | Temperature in studied groups   | <b>78</b>   |
| <b>9</b>    | Serum total bilirubin in studied groups   | <b>79</b>   |
| <b>10</b>   | Focal lesions in both groups  | <b>80</b>   |
| <b>11</b>   | Presence of internal echoes in ascites in both groups                                 | <b>81</b>   |
| <b>12</b>   | Studied groups according to Child Pugh classification                                 | <b>82</b>   |
| <b>13</b>   | Ascitic fluid physical examination among the studied patients.                        | <b>83</b>   |
| <b>14</b>   | AFLAC levels in both groups   | <b>84</b>   |
| <b>15</b>   | Ascitic fluid characters of both groups   | <b>85</b>   |
| <b>16</b>   | Impact of treatment on ascitic fluid chemical composition among the SBP group         | <b>86</b>   |
| <b>17</b>   | Impact of treatment on the results of multistix among the SBP group                   | <b>87</b>   |
| <b>18</b>   | ROC curve of AFLAC  | <b>88</b>   |
| <b>19</b>   | ROC curve of Multistix  | <b>89</b>   |

## **LIST OF ABBREVIATIONS**

|               |   |
|---------------|---|
| <b>AFLAC</b>  | Ascitic fluid lactoferrin.                    |
| <b>ALT</b>    | Alanine transaminase.                         |
| <b>CNNA</b>   | Culture negative neutrocytic ascites          |
| <b>GE</b>     | Granulocyte elastase                          |
| <b>HBV</b>    | Hepatitis B virius.                           |
| <b>HCC</b>    | Hepatocellular carcinoma.                     |
| <b>HCV</b>    | Hepatitis C virus.                            |
| <b>HRS</b>    | Hepatorenal syndrome.                         |
| <b>ICAM-1</b> | Intercellular adhesion molecules-1            |
| <b>IL-1</b>   | Interleukin-1.                                |
| <b>IL-6</b>   | Interleukin-6.                                |
| <b>IL-8</b>   | Interleukin-8.                                |
| <b>LDH</b>    | Lactate dehydrogenase.                        |
| <b>LPS</b>    | Lipopolysaccharide.                           |
| <b>MCP-1</b>  | Monocyte chemotactic protein-1.               |
| <b>MNB</b>    | Monomicrobial non neutrocytic bacterascites.  |
| <b>mRNA</b>   | Messenger RNA.                                |
| <b>NO</b>     | Nitric oxide.                                 |
| <b>NPV</b>    | Negative predictive value.                    |
| <b>PMN</b>    | Polymorpho-nuclear leucocyte.                 |
| <b>PNB</b>    | Polymicrobial non neutrocytic bacterascities. |
| <b>PPV</b>    | Positive predictive value.                    |
| <b>SAAG</b>   | Serum ascites albumin gradient.               |
| <b>SBP</b>    | Spontaneous bacterial peritonitis.            |

|                                |   |
|--------------------------------|---|
| <b>SBP-RI</b>                  | Spontaneous bacterial peritonitis-Renal impairment. |
| <b>SIBO</b>                    | Small intestinal bacterial over growth              |
| <b>TNF-<math>\alpha</math></b> | Tumour necrosis factor alpha                        |
| <b>VCAM-1</b>                  | vascular cell adhesion molecule-1                   |
| <b>VEGF</b>                    | Vascular endothelial growth factor                  |